Hybrid Vigor Volume 1 Issue 7

Dear Friends,
 
Welcome to the fourth week of Hybrid Vigor!
 
We provide our usual Monday recap of the Hillside Ugly 20, along with a bonus list—10 names that may be subject to relatively quick premium contraction, as measured by our Hillside Adjusted Risk Point (HARP) score.  
 
We also provide Jeffrey Alton’s review of earnings reports from low-HARP names and talk about several convertibles that look to be providing reasonably attractive entry points.
Along the way, we chat briefly about Herbalife convertibles and a role they might play in the Pershing Square drama.
 
Finally, Kent Bailey has some insights on Biomarin, one of the most fascinating repeat-offending biotech convertible issuers out there.
 
Volatility looks like it’s trying to come back. That means more trading opportunities. We hope you’ll find Hybrid Vigor to be a useful resource in markets quiet and active alike. Thanks again for all your support and feedback.

Click here to download the newsletter

Bill Feingold
Co-Founder and Managing Principal
Hillside Advisors LLC

Hybrid Vigor Volume 1 Issue 5

Welcome to the third week and fifth edition of Hybrid Vigor!

We're starting to get attention in the general media–the Philadelphia Inquirer noted our head of equity research Jeff Alton's thesis, expressed last week and reiterated today, that recent homebuilder weakness is creating a good entry point, especially in some smaller names.

Today we discuss a couple of trade ideas, provide earnings analysis and previews, and give you an updated "Hillside Ugly 20" list of names susceptible to loss as measured by our proprietary Hillside Adjusted Risk Points (HARP).

As always, we thank you for your interest, support, and encouragement.  We look forward to your continued feedback.  We hope you find our summer issues informative and thought provoking and look forward to welcoming yuo as subscribers this fall.

Click here to download the newsletter

Bill Feingold
Co-Founder and Managing Principal
Hillside Advisors LLC